Intra-Cellular Therapies (ITCI) Tops Q2 EPS by 14c, Raises FY Sales Guidance for CAPLYTA

Intra-Cellular Therapies (NASDAQ: ITCI) reported Q2 EPS of ($0.45), $0.14 better than the analyst estimate of ($0.59). Revenue for the quarter came in at $110.8 million versus the consensus estimate of $106.54 million.

Full year 2023 CAPLYTA net product sales guidance increased to $445 to $465 million from the previous range of $430 to $455 million.

For earnings history and earnings-related data on Intra-Cellular Therapies (ITCI) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• CVG to join Russell 2000 and Russell 3000 indexes June 26
• Cerebras Systems (CBRS) Misses Q1 EPS, Revenues Beat